A Single Dose of Peramivir is Effective and Well-Tolerated at Both 300 mg and 600 mg Dose Levels
BIRMINGHAM, Ala., Oct. 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that a double-blind, placebo-controlled, Phase 2 study of intravenous (i.v.) peramivir, administered via a single dose injection in outpatients with acute, uncomplicated influenza, met its primary endpoint of time to alleviation of symptoms for both the 300 mg dose (p=0.0046) and 600 mg dose (p=0.0046). The study was sponsored by BioCryst's partner for peramivir, Shionogi & Co., Ltd.
The poster titled, "A Double-Blind, Placebo-Controlled Study of Intravenous Peramivir in Acute Influenza Patients" (Poster Session # 302: Respiratory Viruses I: Influenza and RSV) will be presented on Tuesday, October 28 from 12:15 p.m. - 1:15 p.m. Eastern Time in Hall C by Dr. Shigeru Kohno, Dean, Nagasaki University Graduate School of Medicine and Professor, Infection Immunology Department, Nagasaki University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
"This Phase 2 study was a critical test of peramivir, which demonstrated for the first time that a single administration of this potent neuraminidase inhibitor can be effective in treating seasonal influenza," said Dr. William P. Sheridan, Chief Medical Officer of BioCryst. "The promising data in outpatient influenza highlights the potential of the compound as a novel and effective influenza therapy and we look forward to learning more about the clinical advantages of peramivir in the upcoming Shionogi-sponsored Phase 3 program."
The randomized, double-blind, placebo-controlled, Phase 2 study
conducted in Japan enrolled 300 patients age 20 to 64, who
'/>"/>
| SOURCE BioCryst Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |